Harvard Bioscience shares are trading higher after the company reported preliminary Q4 results, issued FY26 outlook and outlined its long-term strategic focus areas.

LABD

HBIO

<p>Harvard Bioscience shares are trading higher after the company reported preliminary Q4 results, issued FY26 outlook and outlined its long-term strategic focus areas.</p>

benzinga_article

First Trust NYSE Arca Biotech Index Fd

Invesco Biotechnology & Genome ETF

Direxion S&P Biotech Bear 3X

VanEck Biotech ETF

iShares Biotechnology ETF

Harvard Bioscience

Proshares Ultra Nasdaq Biotech

SPDR S&P Biotech

News